Further analysis of the expression and genomic interaction of identified epitope peptides between HHLA2 and MAGEB5 in relation to specific immune variants provides a good basis of therapeutic approaches to inhibit this reaction and prevent viral effects related to chronic diseases and cancers. This evidence concerns the gene MAGEB5 and cancer.